Novo Nordisk A/S Target of Unusually High Options Trading (NYSE:NVO)

Novo Nordisk A/S (NYSE:NVO) was the recipient of some unusual options trading on Friday. Stock traders acquired 100,752 call options on the company. This represents an increase of 58% compared to the average daily volume of 63,882 call options.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Oral Wegovy adoption is emerging as a potential catalyst. Jim Cramer highlighted accelerating pill prescriptions and argued that Wall Street’s initial negative reaction to Novo’s quarterly performance may have overlooked the company’s underlying strength. Jim Cramer Reevaluates Novo Nordisk as Wegovy Pill Adoption Accelerates
• Positive Sentiment: Unusually high call-option activity suggests some traders are positioning for a rebound: investors purchased roughly 100,752 calls, about 58% above typical volume. This is a market signal rather than a change in fundamentals.
• Positive Sentiment: Novo’s CEO Mike Doustdar said the obesity-drug market will not be dominated by a single company, arguing that patients will value differentiated treatments and that oral options could broaden demand. Novo CEO Says Obesity Market Won’t Be Winner-Take-All Battle With Lilly
• Neutral Sentiment: Zacks Research upgraded Novo Nordisk from “strong sell” to “hold,” indicating reduced bearishness but not a bullish recommendation. Erste Group also issued a fiscal-2026 earnings estimate, though no estimate details were provided.
• Negative Sentiment: Eli Lilly is gaining obesity-drug market share, creating concern that Lilly’s injectable and oral therapies could widen its competitive advantage even as Novo reports record prescriptions for oral Wegovy. Can Novo Nordisk’s GLP-1 Pill Momentum Offset Lilly’s Growing Edge?
• Negative Sentiment: The company’s chief executive acknowledged Lilly’s market-share gains, while an escalating marketing dispute highlights intensifying competition in the strategically important weight-loss market. Novo Nordisk Escalates Weight-Loss War With Eli Lilly

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Certuity LLC increased its holdings in Novo Nordisk A/S by 3.6% in the 4th quarter. Certuity LLC now owns 5,052 shares of the company’s stock worth $257,000 after purchasing an additional 177 shares in the last quarter. Oakworth Capital Inc. grew its holdings in shares of Novo Nordisk A/S by 41.6% during the fourth quarter. Oakworth Capital Inc. now owns 619 shares of the company’s stock worth $31,000 after purchasing an additional 182 shares during the last quarter. Revolve Wealth Partners LLC grew its holdings in shares of Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after purchasing an additional 200 shares during the last quarter. Werba Rubin Papier Wealth Management increased its stake in shares of Novo Nordisk A/S by 6.0% in the fourth quarter. Werba Rubin Papier Wealth Management now owns 4,270 shares of the company’s stock valued at $217,000 after buying an additional 241 shares during the period. Finally, CoreCap Advisors LLC raised its holdings in Novo Nordisk A/S by 4.7% in the 2nd quarter. CoreCap Advisors LLC now owns 5,341 shares of the company’s stock valued at $256,000 after buying an additional 242 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently commented on NVO. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday. Nordea Equity Research upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Friday, June 19th. Weiss Ratings raised shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. Wall Street Zen cut shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Finally, Berenberg Bank set a $47.00 price target on shares of Novo Nordisk A/S in a report on Wednesday. Four equities research analysts have rated the stock with a Buy rating and sixteen have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $64.94.

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock traded down $0.81 during trading on Friday, reaching $45.91. 10,833,924 shares of the company’s stock were exchanged, compared to its average volume of 12,845,990. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $64.16. The company has a market cap of $204.99 billion, a P/E ratio of 11.23, a PEG ratio of 4.23 and a beta of 0.76. The firm’s 50-day moving average price is $47.36 and its 200 day moving average price is $44.51.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%.The business had revenue of $11.98 billion for the quarter. As a group, research analysts anticipate that Novo Nordisk A/S will post 3.41 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently announced a dividend, which will be paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th will be given a $0.5786 dividend. The ex-dividend date is Monday, August 17th. This represents a yield of 254.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 42.79%.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.